TY  - GEN
AU  - Khorana,Alok A
AU  - Soff,Gerald A
AU  - Kakkar,Ajay K
AU  - Vadhan-Raj,Saroj
AU  - Riess,Hanno
AU  - Wun,Ted
AU  - Streiff,Michael B
AU  - Garcia,David A
AU  - Liebman,Howard A
AU  - Belani,Chandra P
AU  - O'Reilly,Eileen M
AU  - Patel,Jai N
AU  - Yimer,Habte A
AU  - Wildgoose,Peter
AU  - Burton,Paul
AU  - Vijapurkar,Ujjwala
AU  - Kaul,Simrati
AU  - Eikelboom,John
AU  - McBane,Robert
AU  - Bauer,Kenneth A
AU  - Kuderer,Nicole M
AU  - Lyman,Gary H
TI  - Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
SN  - 1533-4406
PY  - 2019///0227
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Double-Blind Method
KW  - Factor Xa Inhibitors
KW  - adverse effects
KW  - Female
KW  - Hemorrhage
KW  - chemically induced
KW  - Humans
KW  - Incidence
KW  - Intention to Treat Analysis
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - complications
KW  - Risk Factors
KW  - Rivaroxaban
KW  - Treatment Outcome
KW  - Venous Thromboembolism
KW  - etiology
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1056/NEJMoa1814630
ER  -